The overexpression of NSD2 in multiple myeloma is a consequence of its regulation by a strong IgH enhancer in the NSD2 gene, and this NSD2 overexpression impairs the binding of EZH2 and the reprogramming of the myeloma epigenome because of locally altering the H3K36 and H3K27 methylation patterns [44]. This evidence concerns the gene NSD2 and plasma cell myeloma.